Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 3825819, 12 pages
http://dx.doi.org/10.1155/2016/3825819
Review Article

Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

1Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, China
2Department of Laboratory Medicine, The First People’s Hospital of Jingmen, Jingmen, China
3Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, China

Received 28 June 2016; Revised 23 August 2016; Accepted 31 August 2016

Academic Editor: Tilman Todenhöfer

Copyright © 2016 Changqing Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Andriole, D. Bostwick, O. W. Brawley et al., “The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study,” The Journal of Urology, vol. 185, no. 1, pp. 126–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013,” European Urology, vol. 65, no. 1, pp. 124–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Abdollah, G. Novara, A. Briganti et al., “Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?” Urology, vol. 77, no. 4, pp. 921–925, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. D. Crawford, K. O. Rove, E. J. Trabulsi et al., “Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases,” The Journal of Urology, vol. 188, no. 5, pp. 1726–1731, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., “Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2239–2246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Fleischhacker and B. Schmidt, “Circulating nucleic acids (CNAs) and cancer—a survey,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1775, no. 1, pp. 181–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Jahr, H. Hentze, S. Englisch et al., “DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells,” Cancer Research, vol. 61, no. 4, pp. 1659–1665, 2001. View at Google Scholar · View at Scopus
  9. H. Schwarzenbach, J. Stoehlmacher, K. Pantel, and E. Goekkurt, “Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer,” Annals of the New York Academy of Sciences, vol. 1137, pp. 190–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. I. M. Reis, K. Ramachandran, C. Speer, E. Gordian, and R. Singal, “Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease,” British Journal of Cancer, vol. 113, no. 3, pp. 460–468, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Wroclawski, A. Serpa-Neto, F. L. A. Fonseca et al., “Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients,” Tumor Biology, vol. 34, no. 5, pp. 2921–2927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Feng, F. Gang, X. Li et al., “Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen,” International Urology and Nephrology, vol. 45, no. 4, pp. 1023–1028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Ellinger, P. J. Bastian, K. I. Haan et al., “Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators,” International Journal of Cancer, vol. 122, no. 1, pp. 138–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Altimari, A. D. Grigioni, E. Benedettini et al., “Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer,” American Journal of Clinical Pathology, vol. 129, no. 5, pp. 756–762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Papadopoulou, E. Davilas, V. Sotiriou et al., “Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer,” Oncology Research, vol. 14, no. 9, pp. 439–445, 2004. View at Google Scholar · View at Scopus
  16. D. Allen, A. Butt, D. Cahill, M. Wheeler, R. Popert, and R. Swaminathan, “Role of cell-free plasma DNA as a diagnostic marker for prostate cancer,” Annals of the New York Academy of Sciences, vol. 1022, pp. 76–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Sunami, M. Shinozaki, C. S. Higano et al., “Multimarker circulating DNA assay for assessing blood of prostate cancer patients,” Clinical Chemistry, vol. 55, no. 3, pp. 559–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Wang, Y.-L. Lin, B. Li, Y.-Z. Wang, W.-P. Li, and J.-G. Ma, “Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer,” Journal of International Medical Research, vol. 42, no. 5, pp. 1085–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Okegawa, K. Nutahara, and E. Higashihara, “Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer,” International Journal of Urology, vol. 17, no. 5, pp. 466–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. P. J. Bastian, G. S. Palapattu, S. Yegnasubramanian et al., “CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer,” Journal of Urology, vol. 179, no. 2, pp. 529–535, 2008. View at Google Scholar
  21. M. Rouprêt, V. Hupertan, J. W. F. Catto et al., “Promoter hypermethylation in circulating blood cells identifies prostate cancer progression,” International Journal of Cancer, vol. 122, no. 4, pp. 952–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. F. Whiting, A. W. S. Rutjes, M. E. Westwood et al., “QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies,” Annals of Internal Medicine, vol. 155, no. 8, pp. 529–536, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. J. Deeks, “Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests,” British Medical Journal, vol. 323, no. 7305, pp. 157–162, 2001. View at Google Scholar · View at Scopus
  24. L. E. Moses, D. Shapiro, and B. Littenberg, “Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations,” Statistics in Medicine, vol. 12, no. 14, pp. 1293–1316, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Jackson, I. R. White, and S. G. Thompson, “Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses,” Statistics in Medicine, vol. 29, no. 12, pp. 1282–1297, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  26. O. E. Bryzgunova, E. S. Morozkin, S. V. Yarmoschuk, V. V. Vlassov, and P. P. Laktionov, “Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients,” Annals of the New York Academy of Sciences, vol. 1137, pp. 222–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Reibenwein, D. Pils, P. Horak et al., “Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance,” Prostate, vol. 67, no. 4, pp. 427–432, 2007. View at Google Scholar · View at Scopus
  28. C.-K. Chuang, D.-C. Chu, R.-D. Tzou, S.-I. Liou, J.-H. Chia, and C.-F. Sun, “Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma,” Cancer Detection and Prevention, vol. 31, no. 1, pp. 59–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Jerónimo, H. Usadel, R. Henrique et al., “Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer,” Urology, vol. 60, no. 6, pp. 1131–1135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Bastian, G. S. Palapattu, X. Lin et al., “Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy,” Clinical Cancer Research, vol. 11, no. 11, pp. 4037–4043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Goessl, M. Müller, R. Heicappell, H. Krause, and K. Miller, “DNA-based detection of prostate cancer in blood, urine, and ejaculates,” Annals of the New York Academy of Sciences, vol. 945, pp. 51–58, 2001. View at Google Scholar · View at Scopus
  32. J. Ellinger, K. Haan, L. C. Heukamp et al., “CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer,” Prostate, vol. 68, no. 1, pp. 42–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Karachaliou, C. Mayo-de-Las-Casas, M. A. Molina-Vila, and R. Rosell, “Real-time liquid biopsies become a reality in cancer treatment,” Annals of Translational Medicine, vol. 3, no. 3, article 36, 2015. View at Publisher · View at Google Scholar
  34. S. Sestini, M. Boeri, A. Marchiano et al., “Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening,” Oncotarget, vol. 6, no. 32, pp. 32868–32877, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Müller, K. Urban, K. Pantel, and H. Schwarzenbach, “Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia,” Annals of the New York Academy of Sciences, vol. 1075, pp. 222–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Ramachandran, C. G. Speer, S. Fiddy, I. M. Reis, and R. Singal, “Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods,” Anticancer Research, vol. 33, no. 10, pp. 4521–4529, 2013. View at Google Scholar · View at Scopus
  37. A. M. Horning, J. A. Awe, C.-M. Wang et al., “DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence,” Prostate, vol. 75, no. 15, pp. 1790–1801, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Wu, E. Giovannucci, J. Welge, P. Mallick, W.-Y. Tang, and S.-M. Ho, “Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis,” British Journal of Cancer, vol. 105, no. 1, pp. 65–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. F. K.-H. Chun, I. Müller, I. Lange et al., “Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer,” BJU International, vol. 98, no. 3, pp. 544–548, 2006. View at Publisher · View at Google Scholar · View at Scopus